Promising Signal of Efficacy for Adjuvant Nivolumab in Patients with Completely Resected Merkel Cell Carcinoma
Findings from an interim analysis of ADMEC-O study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1533 results
Pirtobrutinib Shows Efficacy in Patients with Heavily Pretreated CLL or SLL Who Had Had Disease Progression During Previous Treatment with a Covalent BTK Inhibitor
Findings from the BRUIN study
Lazertinib Demonstrates Significant Efficacy Improvement Compared with Gefitinib in the First-Line Treatment of EGFR-mutated Advanced NSCLC
Findings from the LASER301 study
Enfortumab Vedotin Plus Pembrolizumab Shows a High Confirmed Objective Response Rate in First-Line Treatment of Cisplatin-Ineligible Patients with Advanced Urothelial Cancer
Findings from the EV-103 randomised Cohort K
EMA Recommends Extension of Therapeutic Indications for Sacituzumab Govitecan
New indication concerns the treatment of patients with advanced HR-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least two additional systemic therapies in the advanced setting
Perioperative Nivolumab Plus Chemotherapy Results in Higher pCR and Longer Survival in Patients with Resectable Stage IIIA or IIIB NSCLC
Findings from the NADIM II study
Newly Developed International Childhood Cancer Core Outcome Set Represents Physical, Psychosocial, and Neurocognitive Outcomes for 17 Common Childhood Cancer Subtypes
A set of core outcomes developed by the International Childhood Cancer Outcome Project
PRO Data Can Help When Deciding Between Neoadjuvant FOLFOX or Fluorouracil-Based Chemoradiation for Locally Advanced Rectal Cancer
Patient reported outcomes from the PROSPECT study
EMA Recommends Extension of Therapeutic Indications for Trifluridine/Tipiracil
New indication concerns the third-line treatment of metastatic colorectal cancer in combination with bevacizumab
FDA Approves Talazoparib with Enzalutamide for HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer
Evidence for efficacy is based on the results from the TALAPRO-2 study
Trastuzumab Deruxtecan in Second-Line Treatment for Patients with HER2-positive Advanced Gastric or Gastro-Oesophageal Junction Cancer
Findings from the DESTINY-Gastric02 study
Utility of a Methylation-Based Multicancer Early Detection Test in Identifying Whom with Symptoms to Investigate for Cancer
Findings from the SYMPLIFY study